| Anergis–Virometix: allergy immunotherapy, 202007– collab research study at HZI using SVLPs supported by TRANSVAC2 grant in house dust mite allergy |
2020-07-09 |
| CirQuest Labs–MLM Medical Labs: investment, 202007 acquisition of CirQuest Labs by MLM Medical Labs |
2020-07-08 |
| Osivax–Trophic Communications: public relations, 202007 service existent by Trophic Communications |
2020-07-08 |
| Sanofi–Kiadis: NK cell therapy, 202007– license ww excl for K-NK004 program + two other programs €17.5m upfront + €857.5m milestones + royalties |
2020-07-08 |
| Resistell–EU (govt): grant, 202007 up to €2.5m grant + equity financing offer from EIC programme/fund |
2020-07-03 |
| CRISPR Therapeutics–SEVERAL: investment, 202006– public offering $450m+67.5m with 6.43m+964.3k common shares at $70/share |
2020-06-29 |
| Cutiss–Gisev Family Office: investment, 202006 financing round Series B totalling CHF20m incl lead investor Gisev Familiy Office |
2020-06-29 |
| Cutiss–SEVERAL: investment, 202006 financing round Series B CHF20m led by Gisev Familiy Office |
2020-06-29 |
| RareCyte–Scienion: single-cell dispenser, 202006 supply existent of cellenONE to RareCyte for CTC analysis technology by Cellenion |
2020-06-22 |
| Kaia Health–SEVERAL: investment, 202006 financing round Series B $26m bringing total funds raised to $50m |
2020-06-18 |
| Univ Bochum–Max Planck: antibiotics research, 202006– collab establishment CESAR Center for Antibiotics Research at Univ Bochum with LDC |
2020-06-18 |
| Univ Bochum–North Rhine-Westphalia (govt): grant, 202006– grant €4m from NRW + EFRO for establishment CESAR Center for Antibiotics Research with LDC |
2020-06-18 |
| DiogenX–Boehringer: investment, 202006 seed financing round totalling €4.5m incl investor BIVF |
2020-06-16 |
| DiogenX–SEVERAL: investment, 202006 seed financing round €4.5m from Advent France Biotechnology + BIVF + JDRF T1D Fund |
2020-06-16 |
| eTheRNA–Boehringer: investment, 202006 financing round Series B totalling €34m incl existing investor BIVF |
2020-06-16 |
| eTheRNA–SEVERAL: investment, 202006 financing round Series B €34m from all existing + new investors |
2020-06-16 |
| Qurient–Max Planck: proteasome inhibitors, 2012006– collab develop + license + founding of joint venture QLi5 Therapeutics GmbH |
2020-06-16 |
| CureVac–Germany (govt): investment, 202006 investment €300m direct equity investment by KfW |
2020-06-15 |
| Bit Bio–BY Capital: investment, 202006 financing round Series A totalling $41.5m incl co-investor BlueYard Capital |
2020-06-13 |
| Bit Bio–Mission Group: public relations, 202006 service existent by April Six |
2020-06-13 |
| Bit Bio–SEVERAL: investment, 202006 financing round Series A $41.5m led by Rick Klaunser + Bob Nelsen + Jim Tananbaum |
2020-06-13 |
| Lexent Bio–Roche: investment, 202006 acquisition of Lexent Bio by Foundation Medicine |
2020-06-12 |
| 10x Genomics–Merck (DE): CRISPR technology, 202006 collab launch integrated solution for CRISPR research |
2020-06-10 |
| Bioqube Ventures–Belgium (govt): investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl investor Belfius Insurance |
2020-06-10 |
| Bioqube Ventures–Belgium (govt): investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl investor FPIM |
2020-06-10 |
| Bioqube Ventures–EU (govt): investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl investor EIF |
2020-06-10 |
| Bioqube Ventures–Flanders (govt): investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl investor PMV |
2020-06-10 |
| Bioqube Ventures–Genmab: investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl strategic investor Genmab |
2020-06-10 |
| Bioqube Ventures–JnJ: investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl strategic investor JnJ Innovation |
2020-06-10 |
| Bioqube Ventures–Molenwater Groep: investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl investor Molenwater Groep |
2020-06-10 |
| Bioqube Ventures–SEVERAL: investment, 202006 first closing €60m of Bioqube Factory Fund I investors incl EIF + PMV + FPIM + Genmab + JJDC et al |
2020-06-10 |
| Royalty Pharma–AiCuris: letermovir, 202006 acquisition of partial royalty interest on letermovir for one-time payment of $220m by Royalty Pharma |
2020-06-09 |
| BRAIN–SEVERAL: investment, 202006 private placenment €14.94m with 1.8m new shares at €8.3/share |
2020-06-03 |
| AdvanceCor–Bavaria (govt): investment, 202006 financing round totalling €3.9m incl existing + co-investor Bayern Kapital |
2020-06-02 |
| AdvanceCor–First Capital Partner: investment, 202006 financing round totalling €3.9m incl co-investor First Capital Partner |
2020-06-02 |
| AdvanceCor–Germany (govt): investment, 202006 financing round totalling €3.9m incl existing + co-investor KfW Bank |
2020-06-02 |
| AdvanceCor–MIG Fonds: investment, 202006 financing round totalling €3.9m incl existing + lead investor MIG AG |
2020-06-02 |
| AdvanceCor–Occident Group: investment, 202006 financing round totalling €3.9m incl existing + co-investor Occident |
2020-06-02 |
| AdvanceCor–SEVERAL: investment, 202006 financing round €3.9m led by MIG AG |
2020-06-02 |
| Genmab–Rentschler: biologics contract manufacturing, 202005– collab expansion production of DuoBody products to new Rentschler US facility |
2020-05-27 |
| KI-SIGS project–Germany (govt): grant, 202005– funding €10m from German federal government |
2020-05-27 |
| Kumovis–Ffilipa Venture Capital: investment, 202005 financing round Series A totalling €3.6m incl existing + co-investor Ffilipa Venture Capital |
2020-05-27 |
| Kumovis–High-Tech Gründerfonds: investment, 202005 financing round Series A totalling €3.6m incl existing + co-investor HTGF |
2020-05-27 |
| Kumovis–Renolit: investment, 202005 financing round Series A totalling €3.6m incl new + co-lead investor Renolit SE |
2020-05-27 |
| Kumovis–SEVERAL: investment, 202005 financing round Series A €3.6m led by Renolit + Solvay Ventures |
2020-05-27 |
| Kumovis–Solvay: investment, 202005 financing round Series A totalling €3.6m incl new + co-lead investor Solvay Ventures |
2020-05-27 |
| Exscientia–SEVERAL: investment, 202005 financing round Series C $60m led by Novo Holdings + incl Evotec + BMS + GT Healthcare Capital |
2020-05-26 |
| Spindiag–Baden-Württemberg (govt): grant, 202004 grant €6m for Spindiag + HSI-IMIT from Ministry of Economic Affairs |
2020-05-26 |
| Spindiag–SEVERAL: investment, 202005 financing round Series B €16.3m with investors WBG Pflegeheime + Think-Health Ventures et al. |
2020-05-26 |
| Spindiag–Think.Health Ventures: investment, 202005 financing round Series B totalling €16.3m incl new investor Think.Health Ventures |
2020-05-26 |
| Spindiag–WBG Pflegeheime: investment, 202005 financing round Series B totalling €16.3m incl existing investor WBG Pflegeheime |
2020-05-26 |
| Sterna Biologicals–MC Services: public relations, 202005 service existent by MC Services |
2020-05-26 |
| Sterna Biologicals–SEVERAL: investment, 202005 private placement €12m with existing + new investors |
2020-05-26 |
| Themis Bioscience–Merck (US): investment, 202005– acquisition €na all remaing shares of Themis via Merck subsidiary |
2020-05-26 |
| Poxel–Trophic Communications: public relations, 202005 service existent IR+ media EU/US by Trophic Communications |
2020-05-25 |
| Stratos–Roche: investment, 202005 acquisition €na of Stratos Genomics by Roche |
2020-05-22 |
| Idorsia–SEVERAL: investment, 202005 capital increase CHF330m offering of 11m new shares at CHF30/share to qualified investors |
2020-05-19 |
| Rentschler–Horizon Discovery: cell line development, 202005– license to CHOSource platform for cell line developm for difficult-to-express proteins |
2020-05-19 |
| Rentschler–MC Services: public relations, 202005 service existent by MC Services |
2020-05-19 |
| Apeiron–Austria (govt): grant, 202005– grant funding + guarantees €5.6m from FFG + WAW + AWS + Erste Bank |
2020-05-18 |
| Apeiron–SEVERAL: investment, 202005–202006 private placement €11.9m led by Vienna Insurance Group plus existing + new investors |
2020-05-18 |
| Apeiron–Vienna Insurance Group: investment, 202005–202006 private placement totalling €11.9m incl €7m from new + lead investor VIG |
2020-05-18 |
| Enzymicals–Syngulon: enzyme production technology, 202005– license non-excl to antibiotic-free selection technology of Syngulon |
2020-05-16 |
| OTHER–Enzymicals: enzymes, 202005 service production + supply of diagnostic enzymes using antibiotic-free production for undisclosed world leader |
2020-05-16 |
| Oribiotech–CellGenix: reagents, 202005– collab supply of GMP raw materials for closed-system CGT manufacturing system of Ori |
2020-05-13 |
| Polyganics–EU (govt): grant, 202005 EFRO grant €1.2m for clinical development of Liver + Pancreas Sealant Patch |
2020-05-13 |
| Bluebird Bio–Hitachi: contract manufacturing, 202005– supply expansion long-term developm + manufacturing by HCATS + Apceth for gene therapies |
2020-05-11 |
| Novartis–Dyno Therapeutics: gene therapy, 202005– collab design of AVV vectors for ophthalmic gene therapies using AI-based CapsidMap platform |
2020-05-11 |
| Pluristem–Dentons: legal services, 202005 supply service Dentons is adivsor with regard to €50m EIB loan financing |
2020-05-05 |
| ADC Therapeutics–Deerfield: credit, 202005– convertible credit facility $115m in two conditionable disbursements of $65m + $50m |
2020-05-01 |
| Moderna–Lonza: biologicals contract manufacturing, 202005–203004 collab strategic 10y manufacture of mRNA1273 vaccine + other Moderna products |
2020-05-01 |
| Pfizer–Valneva: Lyme disese vaccine, 202004– collab developm of VLA15 + commerc by Pfizer $130m upfront + $178m milestones + 2-digit tiered royalties |
2020-04-30 |
| Kurma–EU (govt): investment, 202004 final closing of Kurma Biofund III totalling €160m incl investor EIF |
2020-04-29 |
| Kurma–Institut Pasteur: investment, 202004 final closing of Kurma Biofund III totalling €160m incl investor Pasteur Institute |
2020-04-29 |
| Kurma–North Rhine-Westphalia (govt): investment, 202004 final closing of Kurma Biofund III totalling €160m incl investor NRW.BANK |
2020-04-29 |
| Kurma–SEVERAL: investment, 202004 final closing of Kurma Biofund III with €160m |
2020-04-29 |
| Genedata–Cergentis: genomic software tools, –202004 collab developm of Genedata Selector s/w for automating TLA data analysis workflow |
2020-04-28 |
| Gustave Roussy–Biognosys: MS-based proteomics, 202004– collab using proteomic profiling in attempt to repurpose tocilizumab for Covid-19 |
2020-04-28 |
| Compass Pathways–ATAI Life Sciences: investment, 202004 financing round Series B totalling $80m incl existing investor ATAI Life Sciences |
2020-04-27 |
| Compass Pathways–SEVERAL: investment, 202004 financing round Series B $80m from existing + new investors |
2020-04-27 |
| Heidelberg Pharma–Hopp Group: investment, 202004 private placement totalling €14.4m incl €13.7m from main investor Dievini Hopp |
2020-04-27 |
| Heidelberg Pharma–OTHER: investment, 202004 private placement totalling €14.4m incl €719k to institutional investors |
2020-04-27 |
| Heidelberg Pharma–SEVERAL: investment, 202004 private placement €14.4m with 2.82m new shares at €5.1/share incl €13.7m from Dievini Hopp |
2020-04-27 |
| ADC Therapeutics–SEVERAL: investment, 202004– IPO at NYSE filed 2nd time with SEC |
2020-04-24 |
| Pluristem–EU (govt): credit, 202004– EIB financing up to €50m in three milestone-dependent tranches |
2020-04-24 |
| FoRx Therapeutics–Life Sciences Partners: investment, 202004 seed financing round totalling €10m incl co-investor LSP |
2020-04-22 |
| FoRx Therapeutics–Merck (DE): investment, 202004 seed financing round totalling €10m incl co-lead investor M Ventures |
2020-04-22 |
| FoRx Therapeutics–Novartis: investment, 202004 seed financing round totalling €10m incl co-lead investor Novartis Venture Fund |
2020-04-22 |
| FoRx Therapeutics–Omega Funds: investment, 202004 seed financing round totalling €10m incl co-lead investor Omega Funds |
2020-04-22 |
| FoRx Therapeutics–Optimum Strategic Communications: public relations, 202004 service existent by Optimum |
2020-04-22 |
| FoRx Therapeutics–Pfizer: investment, 202004 seed financing round totalling €10m incl co-investor Pfizer Ventures |
2020-04-22 |
| FoRx Therapeutics–SEVERAL: investment, 202004 seed financing round €10m co-led by M Ventures + Novartis Venture Fund + Omega Funds |
2020-04-22 |
| Valneva–Dynavax: SARS-CoV-2 vaccine, 202004– collab development combining Valneva’s vaccine technology with adjuvant CpG 1018 of Dynavax |
2020-04-22 |
| Centogene–Ubirch: blockchain technology, 202004 collab announcing secure blockchain solution for storing SARS-CoV-2 test results |
2020-04-17 |
| Evotec–Leon-Nanodrugs: nanoparticle technology, 202004– collab €na strategic partnership incl equity investment |
2020-04-16 |
| Evox Therapeutics–Cevec: cell line technology, 202004– license €na for use of CAP technology to produce exosome therapeutics as part of ongoing collab |
2020-04-16 |
| Leon-Nanodrugs–Albany Private Equity: investment, 202004 financing round Series B incl existing + co-investor Albany Private Equity Holidngs Pty Ltd |
2020-04-16 |
| Leon-Nanodrugs–Bavaria (govt): investment, 202004 financing round Series B incl new + co-investor BayBG |
2020-04-16 |
| Leon-Nanodrugs–CD-Venture: investment, 202004 financing round Series B incl existing + co-investor CD-Venture GmbH |
2020-04-16 |
| Leon-Nanodrugs–Eckenstein-Geigy-Stiftung: investment, 202004 financing round Series B incl existing + co-investor Eckenstein-Geigy-Stiftung |
2020-04-16 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo-2019.png){kind=logo}
![Picture [iito] Back into Ad 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-back-into-ad.jpg)
Date
![Picture [iito] No Content Marketing 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-no-content-marketing.jpg)
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
